DAMORA THERAPEUTICS, INC. (DMRA) Current Ratio
- Current ratio · latest quarter: Value 19.73×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 19.73× | Current assets / current liabilities. $543.59M ÷ $27.55M ≈ 19.73× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 543.59M USD | Assets, Current |
| Current obligations | 27.55M USD | Liabilities, Current |
| Cash and equivalents | 540.51M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.48M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $543.59M | $27.55M | $540.51M | (m) | (m) | (m) | $3.48M | (m) | 19.73× |
| 2026-03-31 | $535.41M | $23.81M | $532.90M | (m) | (m) | (m) | $819.00K | (m) | 22.48× |
| 2025-12-31 | $260.42M | $20.07M | $257.62M | (m) | (m) | (m) | $444.00K | (m) | 12.98× |
| 2025-09-30 | $9.79M | $2.62M | $7.61M | (m) | (m) | (m) | $520.00K | (m) | 3.73× |
| 2025-06-30 | $13.03M | $2.63M | $10.21M | (m) | (m) | (m) | $756.00K | (m) | 4.96× |
| 2025-03-31 | $14.92M | $1.55M | $11.94M | (m) | (m) | (m) | $354.00K | (m) | 9.62× |
| 2024-12-31 | $16.84M | $1.20M | $14.18M | (m) | (m) | (m) | $377.00K | (m) | 14.07× |
| 2024-09-30 | $21.18M | $2.44M | $19.68M | (m) | (m) | (m) | $503.00K | (m) | 8.68× |
| 2024-06-30 | $25.17M | $3.71M | $22.86M | (m) | (m) | (m) | $724.00K | (m) | 6.79× |
| 2024-03-31 | $30.54M | $4.32M | $21.09M | $6.08M | (m) | (m) | $1.67M | (m) | 7.07× |
| 2023-12-31 | $36.77M | $5.83M | $21.46M | $11.69M | (m) | (m) | $1.70M | (m) | 6.31× |
| 2023-09-30 | $47.05M | $12.55M | $23.08M | $21.10M | (m) | (m) | $4.48M | (m) | 3.75× |
| 2023-06-30 | $55.36M | $14.90M | $22.96M | $29.17M | (m) | (m) | $5.56M | (m) | 3.72× |
| 2023-03-31 | $57.13M | $14.06M | $25.07M | $28.18M | (m) | (m) | $3.55M | (m) | 4.06× |
| 2022-12-31 | $63.91M | $11.11M | $32.79M | $27.44M | (m) | (m) | $3.35M | (m) | 5.75× |
| 2022-09-30 | $71.20M | $8.86M | $28.34M | $40.75M | (m) | (m) | $1.91M | (m) | 8.04× |
| 2022-06-30 | $82.20M | $7.49M | $29.80M | $49.23M | (m) | (m) | $2.81M | (m) | 10.98× |
| 2022-03-31 | $97.03M | $7.21M | $45.39M | $48.21M | (m) | (m) | $3.21M | (m) | 13.45× |
| 2021-12-31 | $110.10M | $4.54M | $62.56M | $37.63M | (m) | (m) | $1.53M | (m) | 24.23× |
| 2021-09-30 | $107.01M | $5.74M | $66.16M | $35.99M | (m) | (m) | $1.98M | (m) | 18.63× |
| 2021-06-30 | $107.71M | $4.75M | $68.64M | $33.18M | (m) | (m) | $1.58M | (m) | 22.65× |
| 2021-03-31 | $116.90M | $5.54M | $74.25M | $36.08M | (m) | (m) | $1.78M | (m) | 21.10× |
| 2020-12-31 | $169.29M | $5.57M | $163.58M | (m) | (m) | (m) | $2.85M | (m) | 30.42× |
| 2020-09-30 | $96.14M | $8.28M | $85.33M | (m) | (m) | (m) | $4.46M | (m) | 11.61× |
| 2019-12-31 | $56.08M | $7.93M | $11.29M | (m) | (m) | (m) | $3.33M | (m) | 7.07× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |